right away, people may look at those and say those sound like small numbers, and they are. these are considered bridging trials. so they re basically looking at their previous adult data and they re sort of bridging it to this pediatric data. not only the number of cases but how many antibodies. were the antibodies good in those that were getting the vaccine? and the data looks really strong. as you point out, even after the first dose, there was significant benefit. after the second dose, essentially no cases of covid in the vaccinated group. we ll see how this plays out. but it should be another candidate for people who want to get the vaccine in that age group. and pfizer got s green light earlier this month to start vaccinating folks in the younger age group. how has that rollout been? you know, it s been going really well. it s interesting to me. i want to show you these numbers. it s about 5% of the population. 12 to 15-year-olds. and what we see now is they